Japan has achieved a historic milestone by granting the world’s first conditional approvals for two stem cell-based regenerative therapies using induced pluripotent stem (iPS) cells.
One therapy, Amchepry developed by Sumitomo Pharma in collaboration with researchers from Kyoto University, targets Parkinson’s disease.
It involves transplanting iPS-derived dopaminergic progenitor cells into the brain to replace lost dopamine-producing neurons, aiming to restore motor function in patients unresponsive to standard treatments like levodopa. Early clinical trials showed promising safety and symptom improvements.
–
.
.
.
